Computational chemistry is already embedded in the drug discovery process. Schrödinger — a company that was founded more than 30 years ago to develop chemical simulation software for biopharmaceutical partners — believes that it should be more foundational still. Having co-founded several biotechs in the past decade, including Nimbus Therapeutics and Morphic Therapeutics, Schrödinger launched its own drug discovery pipeline in 2018 to expand this model. Heading up that effort is Schrödinger Chief Biomedical Scientist Karen Akinsanya. A pharmacologist by training, Akinsanya has more than 20 years industry experience working at the bench, the bedside and then in the boardroom. She now goes back to her research roots, leading the screening of hundreds of billions of compounds against targets of interest. She spoke with Asher Mullard about Schrödinger’s physics-based approach to computational chemistry, the bottlenecks in this approach, and the new opportunities it can open up.

中文翻译：

---

Karen Akinsanya。

计算化学已经嵌入药物发现过程中。Schrödinger是一家成立30多年的公司，致力于为生物制药合作伙伴开发化学模拟软件，该公司认为它应该更加基础。在过去十年中与他人共同创立了包括Nimbus Therapeutics和Morphic Therapeutics在内的几家生物技术公司，Schrödinger于2018年启动了自己的药物发现流程以扩展该模型。负责这项工作的是Schrödinger生物医学首席科学家Karen Akinsanya。经过培训的药剂师，Akinsanya在长凳，床边，然后在董事会工作有20多年的行业经验。现在，她回到了自己的研究根源，带领人们针对感兴趣的目标筛选了数千亿个化合物。